

Clinical trials in the era of personalized oncology

Ca-A Cancer Journal for Clinicians

61, 365-381

DOI: [10.3322/caac.20135](https://doi.org/10.3322/caac.20135)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Trastuzumab and Congestive Heart Failure: What Can We Learn From Use in the Community?. Journal of the National Cancer Institute, 2012, 104, 1269-70.	3.0	2
2	The importance of primary care research in the management of respiratory disease. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2012, 21, 1-3.	2.5	4
3	Epigenetics advancing personalized nanomedicine in cancer therapy. Advanced Drug Delivery Reviews, 2012, 64, 1532-1543.	6.6	35
4	“Personalized Medicine”™ To Identify Genetic Risks For Type 2 Diabetes And Focus Prevention: Can It Fulfill Its Promise?. Health Affairs, 2012, 31, 43-49.	2.5	18
5	BEAMing Up Personalized Medicine: Mutation Detection in Blood. Clinical Cancer Research, 2012, 18, 3209-3211.	3.2	42
6	RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox”Point. Cancer Research, 2012, 72, 5145-5149.	0.4	77
7	Reliable Biomarkers and Predictors of Schizophrenia and its Treatment. Psychiatric Clinics of North America, 2012, 35, 645-659.	0.7	29
8	Modeling NSCLC Progression: Recent Advances and Opportunities Available. AAPS Journal, 2013, 15, 542-550.	2.2	12
9	Predicting outcomes in radiation oncology” multifactorial decision support systems. Nature Reviews Clinical Oncology, 2013, 10, 27-40.	12.5	329
10	Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer. Clinical Chemistry, 2013, 59, 1447-1456.	1.5	44
11	Biological Therapies for Cancer. , 2013, , 303-342.		2
12	Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling. Clinical Pharmacology and Therapeutics, 2013, 93, 345-351.	2.3	11
13	In situ Protein Detection for Companion Diagnostics. Frontiers in Oncology, 2013, 3, 271.	1.3	9
14	Individualizing breast cancer treatment”The dawn of personalized medicine. Experimental Cell Research, 2014, 320, 1-11.	1.2	26
15	Five-year experience with setup and implementation of an integrated database system for clinical documentation and research. Computer Methods and Programs in Biomedicine, 2014, 114, 206-217.	2.6	39
16	Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncology, The, 2014, 15, e8-e21.	5.1	413
17	NOD-scidll2rg tm1Wjl and NOD-Rag1 null ll2rg tm1Wjl : A Model for Stromal Cell”Tumor Cell Interaction for Human Colon Cancer. Digestive Diseases and Sciences, 2014, 59, 1169-1179.	1.1	52
18	Why the Shift? Taking a Closer Look at the Growing Interest in Niche Markets and Personalized Medicine. World Medical and Health Policy, 2015, 7, 3-27.	0.9	8

#	ARTICLE	IF	CITATIONS
19	Data management, documentation and analysis systems in radiation oncology: a multi-institutional survey. <i>Radiation Oncology</i> , 2015, 10, 230.	1.2	8
20	Molecular Imaging to Identify Tumor Recurrence following Chemoradiation in a Hostile Surgical Environment. <i>Molecular Imaging</i> , 2015, 14, 7290.2014.00051.	0.7	3
21	PLGA-Loaded Gold-Nanoparticles Precipitated with Quercetin Downregulate HDAC-Akt Activities Controlling Proliferation and Activate p53-ROS Crosstalk to Induce Apoptosis in Hepatocarcinoma Cells. <i>Molecules and Cells</i> , 2015, 38, 518-527.	1.0	89
22	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2015, 30, 689-721.	2.5	93
23	Review of Developments in Electronic, Clinical Data Collection, and Documentation Systems over the Last Decade – Are We Ready for Big Data in Routine Health Care?. <i>Frontiers in Oncology</i> , 2016, 6, 75.	1.3	14
24	The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies. <i>International Journal of Biological Sciences</i> , 2016, 12, 283-291.	2.6	53
25	Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling. <i>Clinical and Translational Science</i> , 2016, 9, 43-50.	1.5	10
26	The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. <i>Biomedicine and Pharmacotherapy</i> , 2016, 82, 595-605.	2.5	98
27	Clinical trial designs incorporating predictive biomarkers. <i>Cancer Treatment Reviews</i> , 2016, 43, 74-82.	3.4	61
28	Decision support systems for personalized and participative radiation oncology. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 131-153.	6.6	113
30	Managing Expectations in the Transition to Proof of Concept Studies. <i>Reviews on Recent Clinical Trials</i> , 2017, 12, 111-123.	0.4	1
32	Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 6, 17-32.	2.3	17
33	Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-12.	1.0	14
35	Recent advances in “smart” delivery systems for extended drug release in cancer therapy. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 4727-4745.	3.3	179
36	Drug cost avoidance in clinical trials of breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1099-1104.	0.5	11
37	Clinical potential of mass spectrometry-based proteogenomics. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 256-268.	12.5	149
38	Shifting, overlapping and expanding use of “precision oncology” terminology: a retrospective literature analysis. <i>BMJ Open</i> , 2020, 10, e036357.	0.8	8
39	Bayesian Incentive-Compatible Bandit Exploration. <i>Operations Research</i> , 2020, 68, 1132-1161.	1.2	11

#	ARTICLE	IF	CITATIONS
40	The Effect of Quercetin Nanosuspension on Prostate Cancer Cell Line LNCaP via Hedgehog Signaling Pathway. Reports of Biochemistry and Molecular Biology, 2021, 10, 69-75.	0.5	7
41	Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer. Molecules, 2021, 26, 2674.	1.7	15
42	Integrated analysis identifies a novel lncRNA prognostic signature associated with aerobic glycolysis and hub pathways in breast cancer. Cancer Medicine, 2021, 10, 7877-7892.	1.3	6
43	Increased Jab1/COPS5 is associated with therapeutic response and adverse outcome in lung cancer and breast cancer patients. Oncotarget, 2017, 8, 97504-97515.	0.8	5
44	Concordance of folate receptor- β expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients. Oncotarget, 2016, 7, 17442-17454.	0.8	63
45	The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme. Journal of Cancer Therapy, 2014, 05, 929-945.	0.1	14
46	Purposive-Rational Tumor Therapy: Exploiting the Tumor's "Living World" for Diversifying, Specifying and Personalizing Tumor Therapy. , 2013, , 261-288.		0
47	Genomic Expression Profiles: From Molecular Signatures to Clinical Oncology Translation. , 0, , .		0
48	High Efficacy in Hyperthermia-associated with Polyphosphate Magnetic Nanoparticles for Oral Cancer Treatment. Journal of Nanomedicine & Nanotechnology, 2014, 05, .	1.1	2
49	Translation: Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer. Laboratory Medicine Online, 2015, 5, 44.	0.0	0
50	Cancer Diagnosis and Prognosis Assistance Based on MCA. , 2022, , 57-66.		0
51	New challenges in the use of nanomedicine in cancer therapy. Bioengineered, 2022, 13, 759-773.	1.4	40
52	The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update. Frontiers in Immunology, 0, 14, .	2.2	12
54	Identification of potential inhibitor(s) against phospholipase A2 using a network pharmacology-based approach. , 2023, , 15-38.		0
55	Concluding Remarks on Target Nanomedicine: Present and Future Aspects. , 2023, , 343-361.		0